Evaluation of antiarrhythmic drug efficacy in patients with an ICD. Unlimited potential or replete with complexity and problems?

A report from a Study group, proposed by A. J. Camm, London, of the Working Groups on Arrhythmias and Cardiac Pacing of the European Society of Cardiology; co-sponsored by the North American Society of Pacing and Electrophysiology. The Study Group was convened on 29 August 1997 at Saltsjöbaden, nea...

Full description

Saved in:

Bibliographic Details
Published in:	European heart journal Vol. 20; no. 21; pp. 1538 - 1552
Main Authors:	Pratt, C.M, Camm, A.J, Bigger, J.T, Breithardt, G, Campbell, R.W.F, Epstein, A.E, Kappenberger, L.J, Kuck, K.-H, Pocock, S, Saksena, S, Waldo, A.L
Format:	Journal Article
Language:	English
Published:	Oxford Oxford University Press 01-11-1999
Subjects:	Anti-Arrhythmia Agents - therapeutic use Arrhythmias, Cardiac - drug therapy Arrhythmias, Cardiac - etiology Arrhythmias, Cardiac - therapy Biological and medical sciences Cause of Death Clinical Protocols Clinical Trials as Topic Defibrillators, Implantable Diseases of the cardiovascular system Evaluation Studies as Topic Humans Medical sciences Patient Selection Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) Tachycardia - drug therapy Treatment Outcome Human Intensive cardiocirculatory care Arrhythmia Toxicity Treatment efficiency Interference Instrumentation therapy Cardiovascular disease Exploration Chemotherapy Treatment Heart disease Combined treatment Defibrillation Defibrillator
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	A report from a Study group, proposed by A. J. Camm, London, of the Working Groups on Arrhythmias and Cardiac Pacing of the European Society of Cardiology; co-sponsored by the North American Society of Pacing and Electrophysiology. The Study Group was convened on 29 August 1997 at Saltsjöbaden, near Stockholm. The meeting was chaired by A. J. Camm, London, and C. M. Pratt, Houston. Based on the presentation and discussions, a first draft of the documents was prepared by C. Pratt and J. Camm which was then circulated to all members three times for their review. All members of the Study Group approved the final manuscript. This report represents the opinion of the members of this Study Group and does not necessarily reflect the official position of either society. The meeting of the Study Group was made possible by unrestricted educational grants from Medtronic, Guidant, Proctor & Gamble, Berlex and Sanofi. Also, presented, in part, at the Cardio-Renal Drugs Advisory Board meeting of the Food and Drug Administration, Bethesda, Maryland, on 30 April 1999.
Bibliography:	ark:/67375/HXZ-JML01MDN-P istex:29C5AA05C8AC3DAF764376E3060A080035972DE5 local:0.9991850X.1538 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	0195-668X 1522-9645
DOI:	10.1053/euhj.1999.1850